26.73USDMkt Cap: 1.24B USDP/E: —Last update: 2026-05-22
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lea…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap1.24B USD
Enterprise Value931.56M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-166.31M USD
Revenue/Share—
Last Price26.73 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees77
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.01
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.78
EPS (TTM)-3.38
EPS (Forward)-3.37
52W Range
26.4324% of range27.68
52W High27.68 USD
52W Low26.43 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.13%
ROA-49.92%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-160.59M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-6.65%
Net Debt-325.96M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio13.95
Quick Ratio13.06
Book Value/Sh7.150 USD
Cash/Share7.008 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)41.94 USD
Target Range25.25 USD – 50.00 USD
# Analysts12
Ownership
Shares Out.46.57M
Float29.78M
Insiders2.77%
Institutions95.79%
Short Interest
Short Ratio14.0d
Short % Float16.33%
Short % Out.15.33%
Shares Short7.11M
Short (prev mo.)7.76M
Technical
SMA 5026.87 (-0.5%)
SMA 20022.35 (+19.6%)
Beta1.52
S&P 52W Chg28.31%
Avg Vol (30d)425.36K
Avg Vol (10d)355.14K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—